Surface activation and targeting strategies of superparamagnetic iron oxide nanoparticles in cancer-oriented diagnosis and therapy

Nanomedicine

Volumn 5, Issue 1, 2010, Pages 109-133

  Lin, Meng Meng ^a   Kim, Hyung Hwan ^b,c   Kim, Hyuck ^c   Dobson, Jon ^a   Kim, Do Kyung ^a,c,d  

^a KEELE UNIVERSITY   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Jungwon University   (South Korea)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Cancer targeting; Drug delivery; Gene delivery; MRI; Multifunctional nanodevices; Nanocarriers; Spions

Indexed keywords

CAMPTOTHECIN; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FERUCARBOTRAN; FOLATE RECEPTOR; FOLIC ACID; GAMBOGIC ACID; GEFITINIB; GONADORELIN; HYALURONIC ACID; INTEGRIN; LACTOFERRIN; MANNOSE; METHOTREXATE; MITOXANTRONE; NANOSHELL; OCTREOTIDE; PACLITAXEL; PLATINUM COMPLEX; SILICON DIOXIDE; SOMATOSTATIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRANSFERRIN; TRASTUZUMAB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

AQUEOUS SOLUTION; ARTICLE; BLOOD BRAIN BARRIER; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER THERAPY; CARCINOMA; CHEMICAL MODIFICATION; CLINICAL TRIAL; COLON CANCER; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYDROPHOBICITY; HYPERTHERMIC THERAPY; LEUKEMIA; LIGAND BINDING; LIVER CARCINOMA; LUNG CANCER; LUNG CARCINOMA; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM TUMOR; LYMPHOMA; MOLECULAR STABILITY; MYELOMA; NANODEVICE; NANOENCAPSULATION; NANOFABRICATION; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVARY CARCINOMA; PARTICLE SIZE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA;

ANIMALS; DRUG DELIVERY SYSTEMS; FERRIC COMPOUNDS; HUMANS; MAGNETICS; NANOPARTICLES; NEOPLASMS;

EID: 75949111354     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.96     Document Type: Article

References (123)

1. Pankhurst QA, Connoly J, Jones SK, Dobson J: Applications of magnetic nanoparticles in biomedicine. J. Phys. D. 36, R167-R181 (2003).
2. Dobson J: Magnetic nanoparticle-based gene delivery. Gene Deliv. 13, 283-287 (2006).
3. Dobson J: Remote control of cellular behaviour with magnetic nanoparticles. Nat. Nanotechnol. 3, 139-143 (2008).
4. Kim DK, Dobson J: Nanomedicine for targeted drug delivery. J. Mater. Chem. 19, 6294-6307 (2009).
5. Lin MM, Li S, Kim H-H et al.: Complete separation of magnetic nanoparticles via chemical cleavage of dextran by ethylenediamine for intracellular uptake. J. Mater. Chem. DOI: 10.1039/b918416c (2009) (Epub ahead of print).
6. Binder WH, Gloger D, Weinstabl H, Allmaier G, Pittenauer E: Telechelic poly(n-isopropylacrylamides) via nitroxide-mediated controlled polymerization and "click" chemistry: livingness and "grafting-from" methodology. Macromolecules 40, 3097-3107 (2007).
7. Lattuada M, Hatton TA: Functionalization of monodisperse magnetic nanoparticles. Langmuir 23, 2158-2168 (2007).
8. Hu F, Neoh KG, Cen L, Kang E-T: Cellular response to magnetic nanoparticles "PEGylated" via surface-initiated atom transfer radical polymerization. Biomacromolecules 7, 809-816 (2006).
9. 4 nanoparticles: synthesis, characterization and cellular uptake. Biomaterials 28, 5426-5436 (2007).
10. Yoon T-J, Kim JS, Kim BG, Yu KN, ChoM-H, Lee J-K: Multifunctional nanoparticles possessing a "magnetic motor effect" for drug or gene delivery. Angew. Chem. Int. Ed. 44, 1068-1071 (2005).
11. Huo QS, Margolese D, Ciesla U et al.: Generalized synthesis of periodic surfactant inorganic composite-materials. Nature 368 (6469), 317-321 (1994).
12. Giri S, Trewyn BG, Stellmaker MP, Lin VS: Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew. Chem. Int. Ed. 44, 5038-5044 (2005).
13. Chan WCC, Nie SH: Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 281, 2016-2019 (1998).
14. Xu C, Xu K, Gu H et al.: Dopamine as a robust anchor to immobilize functional molecules on the iron oxide shell of magnetic nanoparticles. J. Am. Chem. Soc. 126, 9938-9939 (2004).
15. 4) nanoparticles via trichloro-s-triazine. Chem. Mater. 18, 5401-5403 (2006).
16. De Palma R, Peeters S, Van Bael M et al.: Silane ligand exchange to make hydrophobic superparamagnetic nanoparticles water-dispersible. Chem. Mater. 19, 1821-1831 (2007).
17. Hermanson GT: Bioconjugate Techniques (2nd Edition). Hermanson GT (Ed.). Pierce Biotechnology, Thermo Fisher Scietific, Academic Press, NY, USA (2008).
18. Lin W, Fritz K, Guerin G et al.: Highly luminescent lead sulfide nanocrystals in organic solvents and water through ligand exchange with poly(acrylic acid). Langmuir 24, 8215-8219 (2008).
19. Zhang T, Ge J, Hu Y, Yin Y: A general approach for transferring hydrophobic nanocrystals into water. Nano Lett. 7, 3203-3207 (2007).
20. Na HB, Lee IS, Seo H et al.: Versatile PEG-derivatized phosphine oxide ligands for water dispersible metal oxide nanocrystals. Chem. Comm. 48, 5167-5169 (2007).
21. Qin J, Laurent S, Jo YS et al.: A high-performance magnetic resonance imaging T2 contrast agent. Adv. Mater. 19, 1874-1878 (2007).
22. Shtykova EV, Huang X, Remmes N et al.: Structure and properties of iron oxide nanoparticles encapsulated by phospholipids with poly(ethylene glycol) tails. J. Phys. Chem. 111, 18078-18086 (2007).
23. Xu C, Wang B, Sun S: Dumbbell-like Au-Fe3O4 nanoparticels for target-specific platin delivery. J. Am. Chem. Soc. 131, 4216-4217 (2009).
24. Veiseh O, Gunn JW, Kievit FM et al.: Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small 5, 256-264 (2009).
25. Yang L, Mao H, Wang YA et al.: Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 5, 235-243 (2009).
26. Narain R, Gonzales M, Hoffman AS, StaytonPS, Krishnan KM: Synthesis of monodispers biotinylated p(NIPAAm)-coated iron oxide magnetic nanoparticles and their bioconjugation to straptavidin. Langmuir 23, 6299-6304 (2007).
27. Biju V, Muraleedharan D, Nakayama K et al.: Quantum dot-Insect neuropeptide conjugates for fluorescence imaging, transfection and nucleus targeting of living cells. Langmuir 23, 10254-10261 (2007).
28. Yang C, Rait A, Pirollo KF, Dagata JA, Farkas N, Chang EH: Nanoimmunoliposome delivery of superparamagnetic iron oxide markedly enhances targeting and uptake in human cancer cells in vitro and in vivo. Nanomedicine 4, 318-329 (2008).
29. Choi HS, Liu W, Misra P et al.: Renal clearance of quantum dots. Nat. Biotechnol. 25, 1165-1170 (2007).
30. Schipper ML, Lyer G, Koh AL et al.: Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 5, 126-134 (2009).
31. El-Rayes BF, Lorusso PM: Targeting the epidermal growth factor receptor. B. J. Cancer 91, 418-424 (2004).
32. Yang J, Eom K, Lim E-K et al.: In situ detection of live cancer cells by using bioprobes based on Au nanoparticles. Langmuir 24, 12112-12115 (2008).
33. Feng B, Tomizawa K, Michiue H et al.: Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-his. Biomaterials 30, 1746-1755 (2009).
34. Corezzi S, Urbanelli L, Cloetens P et al.: Synchrotron-based X-ray fluorescence imaging of human cells labeled with CdSe quantum dots. Anal. Biochem. 388, 33-39 (2009).
35. Chen T-J, Cheng T-H, Chen C-Y et al.: Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J. Biol. Inorg. Chem. 14, 253-260 (2009).
36. Loo C, Lowery A, Halas N, West J, Drezek R: Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 5, 709-711 (2005).
37. Eghtedari M, Liopo AV, Copland JA, Oraevsky AA, Motamedi M: Engineering of hetero-functional gold nanorods for the in vivo molecular targeting of breast cancer cells. Nano Lett. 9, 287-292 (2009).
38. Lee S, Chon H, Lee M et al.: Surface-enhanced Raman scattering imaging of HER2 cancer markers overexpressed in single MCF7 cells using antibody conjugated hollow gold nanoparticles. Biosens. Bioelectron. 24, 2260-2263 (2009).
39. Weng KC, Noble CO, Papahadjopoulos-Sternberg B et al.: Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 8, 2851-2857 (2008).
40. Chen J, Wu H, Han D, Xie C: Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy for liver cancer. Cancer Lett. 231, 169-175 (2006).
41. Wu X, Liu H, Liu J et al.: Immunofluorescent labelling of cancer marker HER2 and other cellular targets with semiconductor quantum dots. Nat. Biotechnol. 21, 41-46 (2003).
42. Korpanty G, Carbon JG, Garyburn PA, Fleming JB, Brekken RA: Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin. Cancer Res. 13, 323-330 (2007).
43. Laakkonen P, Akerman ME, Biliran H et al.: Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl Acad. Sci. USA 101, 9381-9386 (2004).
44. Tammela T, Zarkada G, Wallgard E et al.: Blocking VEFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454, 656-660 (2008).
45. Rosenholm JM, Meinander A, Peuhu E et al.: Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano 3, 197-206 (2009).
46. Shi X, Wang SH, Swanson SD et al.: Dendrimer-functionalized shell-crosslinked iron oxide nanoparticles for in-vivo magnetic resonance imaging of tumors. Adv. Mater. 20, 1671-1678 (2007).
47. Wang SH, Shi X, Van Antwerp M et al.: Dendrimer-functionalized iron oxide nanoparticles for specific targeting and imaging of cancer cells. Adv. Func. Mater. 17, 3043-3050 (2007).
48. Bharali DJ, Lucey DW, Jayakumar H, Pudavar HE, Prasad PN: Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. J. Am. Chem. Soc. 127, 11364-11371 (2005).
49. Shi X, Wang S, Meshinchi S et al.: Dendrimer-entrapped gold nanoparticles as a platform for cancer-cell targeting and imaging. Small 7, 1245-1252 (2007).
50. Oh J-M, Choi S-J, Lee G-E, Han S-H, ChoyJ-H: Inorganic drug-delivery nanovehicle conjugated with cancer-cell-specific ligand. Adv. Func. Mater. 19, 1617-1624 (2009).
51. Soppimath KS, Liu LH, Seow WY et al.: Multifunctional core/shell nanoparticles self-assembled from pH-induced thermosensitive polymers for targeted intracellular anticancer drug delivery. Adv. Func. Mater. 17, 355-362 (2007).
52. Kim D, Lee ES, Oh KT, Gao ZG, Bae YH: Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 4, 2043-2050 (2007).
53. Zheng G, Chen J, Li H, Glickson JD: Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl Acad. Sci. USA 102, 17757-17762 (2005).
54. Chen J, Corbin IR, Li H, Cao W, GlicksonJD, Zhang G: Ligand conjugation low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J. Am. Chem. Soc. 129, 5798-5799 (2007).
55. Qian J, Li X, Wei M, Gao X, Xu Z, He S: Bio-molecule-conjugated fluorescent organically modified silica nanoparticles as optical probes for cancer cell imaging. Optics. Expr. 16, 19568-19578 (2008).
56. Li J-L, Wang L, Liu X-Y et al.: In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles. Cancer Lett. 274, 319-326 (2009).
57. Freedman M, Chang EH, Zhou Q, PirolloKF: Nanodelivery of MRI contrast agent enhances sensitivity of detection of lung cancer metastases. Acad. Radiol. 16, 627-637 (2009).
58. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992 (2005).
59. Abhilash V, Babu S, Heckert E et al.: Protonated nanoparticles surface governing ligand tethering and cellular targeting. ACS Nano 3, 1203-1211 (2009).
60. Elfinger A, Maucksch C, Rudolph C: Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials 28, 3448-3455 (2007).
61. Ortiz-Sanchez E, Daniels TR, Helguera G, Martinez-Maza O, Bonavida B, Penichet ML: Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoitetic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia 23, 59-70 (2009).
62. Horak D, Babic M, Jendelova P et al.: D-mannose-modified iron oxide nanoparticles for stem cell labelling. Bioconjug. Chem. 18, (2007).
63. Brevet D, Gary-Bobo M, Raehm L et al.: Mannose-targeted mesoporous silica nanoparticles for photodynamic therapy. Chem. Comm. 12, 1475-1477 (2009).
64. Arnaout MA, Mahalingam B, Xiong JP: Integrin structure, allostery, and bidirectional signaling. Annu. Rev. Cell. Dev. Biol. 21, 381-410 (2005).
65. Achilefu S, Bloch S, Markiewicz MA et al.: Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression. Proc. Natl Acad. Sci. USA 102, 7976-7981 (2005).
66. Lee J-H, Lee K, Moon SH, Lee Y, Park TG, Cheon J: All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew. Chem. Int. Ed. 48, 4174-4179 (2009).
67. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS: Combinational chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging. Nat. Chem. Bio. 2, 381-389 (2006).
68. Liu R, Peng L, Han H, Lam KS: Structure-activity relationship studies of a series of peptidomimetic ligand for α4β1 integrin on Jurkat T-leukemia cells. Biopolymers 84, 595-604 (2006).
69. Pitarresi G, Craparo EF, Palumbo FS, Carlisi B, Giammona G: Composite nanoparticles based on hyaluronic acid chemically crosslinked with α, β-polyaspartylhydrazide. Biomacromolecules. 8, 1890-1898 (2007).
70. Marha R, Zoller M: CD44 in cancer progression: Adhesion, migration and growth regulation. J. Mol. Histol. 35, 211-231 (2004).
71. Dimeo C, Panza L, Captitani D et al.: Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy. Biomacromolecules 8, 552-559 (2007).
72. Varghese OP, Sun W, Hilborn J, OssipovDA: In situ cross-linkable high molecular weight hyaluronan-bisphophonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach. J. Am. Chem. Soc. 131, 8781-8783 (2009).
73. Kelly K, Alencar H, Funovics M, MahmoodU, Weissleder R: Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide. Cancer Res. 64, 6247-6251 (2004).
74. Garg A, Tisdale AW, Haidari E, Kokkoli E: Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm. 366, 201-210 (2009).
75. Demirgoz D, Garg A, Kokkoli E: Pr-b targeted PEGylated liposomes for prostate cancer therapy. Langmuir 24, 13518-13524 (2008).
76. Chittasupho C, Xie S-X, Baoum A, Yakovleva T, Siahaan TJ, Berkland CJ: ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur. J. Pharm. Sci. 37, 141-150 (2009).
77. Veiseh O, Sun C, Gunn J et al.: Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett. 5, 1003-1008 (2005).
78. Veiseh O, Kievit FM, Gunn JW, Ratner BD, Zhang M: A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials 30, 649-657 (2009).
79. Banzato A, Rondina M, Melendez-Alafort L et al.: Biodistribution of a paclitaxel-hyaluronan bioconjugate. Nucl. Med. Biol. 36, 525-533 (2009).
80. Krenning EP, Bakker WH, Breeman WA et al.: Localization of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1, 242-244 (1989).
81. Kostenich G, Livnah N, Bonasera TA et al.: Targeting small-cell lung cancer with novel fluorescent analogs of somatostatin. Lung Cancer 50, 319-328 (2005).
82. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endo. Rev. 24(4), 389-427 (2003).
83. Dasgupta P: Somatostatin analogs: Multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharm. Therap. 102, 61-85 (2004).
84. Kostenich G, Oron-Herman M, Kimel S, Livnah N, Tsarfty I, Orenstein A: Diagnostic targeting of colon cancer using a novel fluorescent somatostatin conjugate in a mouse xenograft model. Int. J. Cancer 122, 2044-2049 (2008).
85. Shen H, Hu D, Du J et al.: Paclitaxel-octreotide conjugates in tumor growth inhibition of a459 human non-small cell lung cancer xenografted into nude mice. Eur. J. Pharm. 601, 23-29 (2009).
86. Li XB, Du XK, Huo TL, Liu X, Zhang S: Specific targeting of breast tumor by octreotide-conjugated superparamagnetic iron oxide particles using a clinical 3.0-tesla magnetic resonance scanner. Acta Radiol. 50, 583-594 (2009).
87. Gozes I: VIP, from gene to behaviour and back: summarizing my 25years of research. J. Mol. Neurosci. 36, 115-124 (2008).
88. Zhang K, Aruva MR, Shanthly N et al.: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogs for PET imaging of breast cancer: in vitro/in vivo evaluation. Regul. Pept. 144, 91-100 (2007).
89. Onyukel H, Jeong JH, Rubinstein I: Nanomicellar paclixatel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 274, 327-330 (2009).
90. Rubinstein I, Soos I, Onyukel H: Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells. Chem. Biol. Interact. 171, 190-194 (2008).
91. Moody TW, Mantey SA, Fuselier JA, Coy DH, Jensen RT: Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells. Peptides 28, 1883-1890 (2007).
92. Dharap SS, Wang Y, Chandna P et al.: Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl Acad. Sci. USA 102, 12962-12967 (2005).
93. Zhou J, Leuschner C, Kumar C, Hormes J, Soboyejo WO: A TEM study of functionalized magnetic nanoparticles targeting breast cancer cells. Mater. Sci. Eng. C. 26, 1451-1455 (2005).
94. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG: LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. Bioconjug. Chem. 19, 2156-2162 (2008).
95. Tietze LF, Panknin O, Major F, Krewer B: Synthesis of a novel pentagastrin-drug conjugate for a targeted tumor therapy. Chem. Eur. J. 14, 2811-2818 (2008).
96. Ma LX, Yu P, Veerendra B et al.: In vitro and in vivo evaluation of Alexa Fluor 680-bombesin [7-14] NH2 peptide conjugate, a high affinity fluorescent probe with high selectivity for the gastrin-releasing peptide receptor. Mol. Imaging 6, 171-180 (2007).
97. 68Ga labeled RGD-bombesin heteropeptides for pet imaging of breast cancer. Bioconjug. Chem. 20, 1016-1025 (2009).
98. Huang CM, Weu YT, Chen SY: Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem. Biol. 7, 453-461 (2000).
99. Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Onyukel H: VIP grafted sterically stabilized liposomes or targeted imaging of breast cancer: in vivo studies. J. Control. Release 91, 123-133 (2003).
100. Dubuc C, Langlois R, Benard F et al.: Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine-bombesin conjugate. Bioorg. Med. Chem. Lett. 18, 2424-2427 (2008).
101. Kim DK, Mikhaylova M, Wang FH et al.: Starch-coated superparamagnetic nanoparticles as MR contrast agents. Chem. Mater. 15, 4343-4351 (2003).
102. Neuwelt EA, Varallyey P, Bago AG, Muldoon LL, Nesbit G, Nixon R: Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol. Appl. Neurobio. 30(5), 456-471 (2004).
103. Zhang Y, Zhang Y-F, Bryant J, Charles A, Boado R, Pardridge WM: Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10, 3667-3677 (2004).
104. Vinogradov SV, Batrakova EV, Kabanov V: Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem. 15, 50-60 (2004).
105. Huang R, Ke W, Liu Y, Jiang C, Pei Y: The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 29, 238-246 (2008).
106. Peer D, Karp JM, Hong S, Farohzard OC, Margalit R, Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
107. Delves PJ, Martin SJ, Burton DR, Roitt IM: Roitt's Essential Immunology (11th Edition). Delves PJ, Martin SJ, Burton DR, Roitt IM (Eds). Wiley-Blackwell Blackwell Publishing, MA, USA (2006).
108. Martin AL, Li B, Gillies ER: Surface functionalization of nanomaterials with dendritic groups: toward enhanced binding to biological targets. J. Am. Chem. Soc. 131, 734-741 (2009).
109. Bjornerud A, Johansson L: The utility of superparamagnetic contrast agents in MRI: theoretical consideration and applications in the cardiovascular system. NMR Biomed. 17, 465-477 (2004).
110. Neuberger T, Schopf B, Hofmann H, Hofmann M, Von Rechenberg B: Superparamagnetic nanoparticle for biomedical applications: possibility and limitations of a new drug delivery system. J. Magn. Magn. Mater. 293, 483-496 (2005).
111. De Bondt RB, Nelemans PJ, Hofman PAM et al.: Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. Eur. J. Radiol. 64, 266-272 (2007).
112. Gneveckow U, Jordan A, Scholz R et al.: Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. Med. Phys. 31(1444-1451), (2004).
113. Ito A, Kuga Y, Honda H et al.: Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett. 212, 161-175 (2004).
114. Hilger I, Hergt R, Kaiser WA: Towards breast cancer treatment by magnetic heating. J. Magn. Magn. Mater. 293, 314-319 (2005).
115. Pankhurst QA, Thanh NKT, Jone ST, Dobson J: Progress in applications of magnetic nanoparticles in biomedicine. J. Phys. D. 42, 2244001-22416 (2009)
116. Widder KJ, Senyi AE: Magnetic microspheres: a model system for site specific drug delivery in vivo. Proc. Soc. Exp. Biol. Med. 58, 141-146 (1978).
117. Senyi AE, Widder KJ, Czerlinski C: Magnetic guidance of drug carrying microspheres. J. Appl. Phys. 49, 3578-3583 (1978).
118. Widder KJ, Morris RM, Poore GA, Howard DP, Senyi AE: Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin-total remission in yoshida sarcoma-bearing rats. Eur. J. Cancer. Clin. Oncol. 19, 135-139 (1983).
119. Alexiou C, Arnold W, Klein RJ et al.: Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60, 6641-6648 (2000).
120. Lemke AJ, Von Pilsach M, Lubbe AS, Bergemann C, Riess H, Felix R: MRI after magnetic drug targeting in patients with advanced solid malignant tumors. Euro. Radiol. 14, 1949-1955 (2004).
121. Dobson J: Magnetic nanoparticle-based targeting for drug and gene delivery. Nanomedicine 1, 31-37 (2006).
122. Dobson J: Magnetic nanoparticles for drug delivery. Drug Dev. Res. 67, 55-60 (2006).
123. Rosengart AJ, Kaminski MD, Chen H, Caviness PI, Ebner AD: Magnetizable implants and functionalized magnetic carriers: a novel approach for noninvasive yet targeted drug delivery. J. Magn. Magn. Mater. 293, 633-638 (2005).